|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
DE69536015D1
(de)
|
1995-03-30 |
2009-12-10 |
Pfizer Prod Inc |
Chinazolinone Derivate
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
AU9598601A
(en)
*
|
2000-10-20 |
2002-04-29 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
CA2604238C
(en)
|
2005-04-15 |
2015-07-07 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
AU2006309551B2
(en)
*
|
2005-11-07 |
2012-04-19 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
|
ES2599458T3
(es)
*
|
2008-10-14 |
2017-02-01 |
Sunshine Lake Pharma Co., Ltd. |
Compuestos y métodos de uso
|
|
NZ779754A
(en)
|
2009-01-16 |
2023-04-28 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
EP2214019A1
(en)
|
2009-01-28 |
2010-08-04 |
Externautics S.p.A. |
Tumor markers and methods of use thereof
|
|
EP2213686A1
(en)
|
2009-01-28 |
2010-08-04 |
Externautics S.p.A. |
Tumor markers and methods of use thereof
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
WO2011051277A1
(en)
|
2009-10-26 |
2011-05-05 |
Externautics S.P.A. |
Breast tumor markers and methods of use thereof
|
|
US10288617B2
(en)
|
2009-10-26 |
2019-05-14 |
Externautics Spa |
Ovary tumor markers and methods of use thereof
|
|
US8921058B2
(en)
|
2009-10-26 |
2014-12-30 |
Externautics Spa |
Prostate tumor markers and methods of use thereof
|
|
EP2494351B1
(en)
|
2009-10-26 |
2016-06-08 |
Externautics S.p.A. |
Colon and rectal tumor markers and methods of use thereof
|
|
WO2011051278A1
(en)
|
2009-10-26 |
2011-05-05 |
Externautics S.P.A. |
Lung tumor markers and methods of use thereof
|
|
US20120070368A1
(en)
*
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
EP2383578A1
(en)
|
2010-04-30 |
2011-11-02 |
Externautics S.p.A. |
Tumor marker and methods of use thereof
|
|
ES2598530T3
(es)
*
|
2010-07-14 |
2017-01-27 |
Betta Pharmaceuticals Co., Ltd. |
Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
|
|
EA030435B1
(ru)
|
2010-07-16 |
2018-08-31 |
Экселиксис, Инк. |
ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
|
|
US8664244B2
(en)
|
2010-09-12 |
2014-03-04 |
Advenchen Pharmaceuticals, LLC |
Compounds as c-Met kinase inhibitors
|
|
MX352926B
(es)
|
2010-09-27 |
2017-12-14 |
Exelixis Inc |
Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
|
|
CN102093421B
(zh)
*
|
2011-01-28 |
2014-07-02 |
北京康辰药业有限公司 |
一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
|
BR112013020362A2
(pt)
|
2011-02-10 |
2018-05-29 |
Exelixis Inc |
processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
MX2013012695A
(es)
|
2011-05-02 |
2014-03-27 |
Exelixis Inc |
Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
|
|
CN102408411B
(zh)
*
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
CN104395284A
(zh)
|
2011-10-20 |
2015-03-04 |
埃克塞里艾克西斯公司 |
制备喹啉衍生物的方法
|
|
TW201323864A
(zh)
|
2011-11-08 |
2013-06-16 |
Exelixis Inc |
定量癌症治療之方法
|
|
IN2014CN04067A
(enExample)
|
2011-11-08 |
2015-10-23 |
Exelixis Inc |
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
JP6513567B2
(ja)
|
2012-09-07 |
2019-05-15 |
エクセリクシス， インク． |
肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
CA2907334C
(en)
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
WO2014165779A1
(en)
|
2013-04-04 |
2014-10-09 |
Exelixis, Inc. |
Drug combinations to treat cancer
|
|
SMT202100065T1
(it)
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
EP3008086A2
(en)
|
2013-06-14 |
2016-04-20 |
Externautics S.p.A. |
Tumor marker, monoclonal antibodies and methods of use thereof
|
|
IL292510A
(en)
|
2013-11-05 |
2022-06-01 |
Cognate Bioservices Inc |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
BR112016018450A2
(pt)
|
2014-02-14 |
2018-09-18 |
Exelixis Inc |
formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
|
|
EP3119476A1
(en)
|
2014-03-17 |
2017-01-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
UA121655C2
(uk)
|
2014-04-25 |
2020-07-10 |
Екселіксіс, Інк. |
Спосіб лікування аденокарциноми легень
|
|
EP3174854B1
(en)
|
2014-07-31 |
2022-08-24 |
Exelixis, Inc. |
Method of preparing fluorine-18 labeled cabozantinib and its analogs
|
|
MX382904B
(es)
|
2014-08-05 |
2025-03-13 |
Exelixis Inc |
Combinaciones de fármacos para tratar mieloma múltiple.
|
|
CN104817497B
(zh)
*
|
2015-03-20 |
2017-03-08 |
南京众睿缘生物科技有限公司 |
一种炔代喹啉衍生物及其制备方法和用途
|
|
CN106279147A
(zh)
|
2015-05-21 |
2017-01-04 |
中国科学院上海药物研究所 |
一种吡啶并氮杂环化合物及其制备方法和用途
|
|
US20160376239A1
(en)
*
|
2015-06-29 |
2016-12-29 |
Ontogenesis, Llc |
N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
|
|
US20180009758A1
(en)
*
|
2015-06-29 |
2018-01-11 |
Ontogenesis, Llc |
Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
|
|
US20170342033A1
(en)
*
|
2015-06-29 |
2017-11-30 |
Ontogenesis, Llc |
Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
|
|
EP3442531A1
(en)
|
2016-04-15 |
2019-02-20 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
|
|
CN109475545A
(zh)
|
2016-04-19 |
2019-03-15 |
埃克塞里艾克西斯公司 |
三阴性乳腺癌治疗方法
|
|
CN105797123A
(zh)
|
2016-05-18 |
2016-07-27 |
王超 |
一种治疗不孕不育的中药组合物
|
|
CN106400155A
(zh)
|
2016-08-31 |
2017-02-15 |
飞佛特种纺织品（宁波）有限公司 |
一种防老化阳光面料
|
|
CN107235896B
(zh)
*
|
2016-09-13 |
2019-11-05 |
上海翔锦生物科技有限公司 |
酪氨酸激酶抑制剂及其应用
|
|
WO2018064191A1
(en)
|
2016-09-27 |
2018-04-05 |
The Usa Of America, As Represented By The Secretary, Department Of Health & Human Services |
Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US11198731B2
(en)
|
2017-01-20 |
2021-12-14 |
Exelixis, Inc. |
Combinations of cabozantinib and atezolizumab to treat cancer
|
|
CN110049969A
(zh)
*
|
2017-02-07 |
2019-07-23 |
恩瑞生物医药科技（上海）有限公司 |
喹啉类化合物、其制备方法及其医药用途
|
|
MA48776A
(fr)
|
2017-05-26 |
2020-04-08 |
Exelixis Inc |
Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
|
|
AU2018279834B2
(en)
|
2017-06-09 |
2024-05-23 |
Exelixis, Inc. |
Liquid dosage forms to treat cancer
|
|
SG11202005719UA
(en)
|
2017-12-20 |
2020-07-29 |
Angex Pharmaceutical Inc |
Carbamate and urea compounds as multikinase inhibitors
|
|
US20190262330A1
(en)
|
2017-12-21 |
2019-08-29 |
Exelixis, Inc. |
Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
|
|
CR20250117A
(es)
*
|
2018-01-26 |
2025-05-09 |
Exelixis Inc |
COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355)
|
|
CN117402114A
(zh)
*
|
2018-01-26 |
2024-01-16 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
|
CA3088198A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
|
KR102828472B1
(ko)
*
|
2018-12-13 |
2025-07-03 |
엑셀리시스, 인코포레이티드 |
키나아제 억제제의 결정질 형태 및 염 형태
|
|
BR112021014504A2
(pt)
*
|
2019-01-25 |
2021-09-28 |
Exelixis, Inc. |
Compostos para o tratamento de transtornos dependentes de cinase
|
|
MX2021014773A
(es)
*
|
2019-06-03 |
2022-01-18 |
Exelixis Inc |
Formas de sales cristalinas de un inhibidor de cinasas.
|
|
AR119069A1
(es)
*
|
2019-06-04 |
2021-11-24 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de quinasas
|
|
CN115461328B
(zh)
*
|
2020-04-30 |
2025-11-07 |
埃克塞里艾克西斯公司 |
用于制备激酶抑制剂的方法
|
|
IL300151A
(en)
*
|
2020-07-31 |
2023-03-01 |
Exelixis Inc |
Combinations for cancer treatment
|
|
JP2023548855A
(ja)
*
|
2020-11-05 |
2023-11-21 |
エグゼリクシス， インコーポレイテッド |
キナーゼ阻害剤の医薬組成物
|
|
TW202334090A
(zh)
*
|
2021-11-03 |
2023-09-01 |
美商艾克塞里克斯公司 |
用於治療激酶依賴性病症之化合物
|
|
US20250368606A1
(en)
*
|
2021-12-22 |
2025-12-04 |
Exelixis, Inc. |
Crystalline forms and salt forms of a kinase inhibitor
|